HCV
MCID: HPT073
MIFTS: 74

Hepatitis C Virus (HCV)

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Hepatitis C Virus

MalaCards integrated aliases for Hepatitis C Virus:

Name: Hepatitis C Virus 57
Hepatitis C Virus, Susceptibility to 57 29 6 40
Hepatitis C Virus Infection, Response to Therapy of 57 29 6
Response to Antiviral Treatment in Hepatitis C 59
Hepatitis C Virus, Response to Therapy of 57
Response to Peg/ifn-Ribavirin in Hcv 59
Hepatitis C Virus, Resistance to 57
Resistance to Hepatitis C Virus 6
Hcv, Susceptibility to 57
Hcv 57

Classifications:



External Ids:

OMIM 57 609532
Orphanet 59 ORPHA284102

Summaries for Hepatitis C Virus

OMIM : 57 HCV, which is principally transmitted by blood, infects about 3% of the world's population. HCV infection causes acute hepatitis, which is self-resolving in 20 to 50% of cases but does not confer permanent immunity. In 50 to 80% of cases, HCV infection becomes chronic and results in chronic hepatitis, cirrhosis, and hepatocellular carcinoma. As a result, HCV infection is a leading killer worldwide and the most common cause of liver failure in the U.S. HCV is opportunistic in individuals infected with human immunodeficiency virus (HIV; see 609423), approximately 25% of whom are coinfected with HCV. HCV infection is also associated with cryoglobulinemia (see 123550), a B-lymphocyte proliferative disorder (Pawlotsky, 2004; Chisari (2005); Pileri et al., 1998). (609532)

MalaCards based summary : Hepatitis C Virus, also known as hepatitis c virus, susceptibility to, is related to hepatitis c and hepatitis. An important gene associated with Hepatitis C Virus is IFNG (Interferon Gamma), and among its related pathways/superpathways are JAK-STAT signaling pathway (KEGG) and Blood-Brain Barrier Pathway: Anatomy. The drugs Guaifenesin and Methadone have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and t cells, and related phenotypes are Decreased JFH-1 genotype 2a Hepatitis C virus (HCV) infection and hematopoietic system

Related Diseases for Hepatitis C Virus

Diseases in the Hepatitis family:

Hepatitis C Virus Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis B Hepatitis D
Autoimmune Hepatitis Hepatitis E

Diseases related to Hepatitis C Virus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1037)
# Related Disease Score Top Affiliating Genes
1 hepatitis c 34.3 SCARB1 KRT18 IFNL4 IFNG HM13 GPT
2 hepatitis 33.1 SCARB1 PSMA7 KRT8 KRT18 IFNL4 GPT
3 viral infectious disease 32.4 IFNG GPT CD81 CCR5
4 hepatitis d 31.9 IFNL3 GPT
5 cryptogenic cirrhosis 31.7 KRT8 KRT18
6 recurrent hepatitis c virus induced liver disease in liver transplant recipients 12.5
7 hepatocellular carcinoma 12.0
8 lichen planus 11.8
9 polyarteritis nodosa 11.7
10 immunotactoid glomerulopathy 11.7
11 fibrillary glomerulonephritis 11.7
12 gianotti crosti syndrome 11.3
13 immunotactoid or fibrillary glomerulopathy 11.3
14 liver disease 11.3
15 liver cirrhosis 11.3
16 cryoglobulinemia 11.1
17 cryoglobulinemia, familial mixed 11.0
18 viral hepatitis 11.0
19 vasculitis 11.0
20 hepatitis b 11.0
21 glomerulonephritis 11.0
22 immune deficiency disease 10.9
23 neurenteric cyst 10.9 KRT8 KRT18
24 proliferating trichilemmal cyst 10.9 KRT8 KRT18
25 end stage renal failure 10.8
26 cutaneous adenocystic carcinoma 10.8 KRT8 KRT18
27 membranoproliferative glomerulonephritis 10.8
28 fatty liver disease, nonalcoholic 1 10.8
29 hepatitis a 10.8
30 lymphoma 10.8
31 b-cell lymphoma 10.8
32 human immunodeficiency virus type 1 10.8
33 vaccinia 10.8
34 purpura 10.8
35 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.8
36 porphyria 10.8
37 chronic kidney disease 10.8
38 porphyria cutanea tarda 10.8
39 odontoma 10.8 KRT8 KRT18
40 autoimmune disease 10.7
41 hemophilia 10.7
42 autoimmune hepatitis 10.7
43 alcohol use disorder 10.7
44 fatty liver disease 10.7
45 kidney disease 10.7
46 thrombocytopenia 10.7
47 cervical clear cell adenocarcinoma 10.7 KRT8 KRT18
48 lymphoma, hodgkin, classic 10.7
49 lymphoma, non-hodgkin, familial 10.7
50 hemosiderosis 10.7

Graphical network of the top 20 diseases related to Hepatitis C Virus:



Diseases related to Hepatitis C Virus

Symptoms & Phenotypes for Hepatitis C Virus

Clinical features from OMIM:

609532

GenomeRNAi Phenotypes related to Hepatitis C Virus according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased JFH-1 genotype 2a Hepatitis C virus (HCV) infection GR00233-A-1 9.02 CD81 CLDN1 GPT HM13 PNKD

MGI Mouse Phenotypes related to Hepatitis C Virus:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.85 ATG5 CCR5 CD81 CLEC4M HM13 IFNG
2 immune system MP:0005387 9.65 ATG5 CCR5 CD81 CLEC4M HM13 IFNG
3 liver/biliary system MP:0005370 9.23 ATG5 CCR5 HM13 IFNG KRT18 KRT8

Drugs & Therapeutics for Hepatitis C Virus

Drugs for Hepatitis C Virus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 456)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
2
Methadone Approved, Illicit Phase 4 76-99-3 4095
3
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
4
Insulin glulisine Approved Phase 4 207748-29-6
5
Insulin glargine Approved Phase 4 160337-95-1
6
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
7
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
8
Mycophenolic acid Approved Phase 4 24280-93-1 446541
9
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
10
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616 46835353
11
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
12
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
13
Fosamprenavir Approved Phase 4 226700-79-4 131536
14
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
15
Polyestradiol phosphate Approved Phase 4 28014-46-2
16
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
17
Metformin Approved Phase 4 657-24-9 4091 14219
18
Promethazine Approved, Investigational Phase 4 60-87-7 4927
19
Histamine Approved, Investigational Phase 4 51-45-6 774
20
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
21
Nelfinavir Approved Phase 4 159989-64-7 64143
22
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
23
Zidovudine Approved Phase 4 30516-87-1 35370
24
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
25
Cobicistat Approved Phase 4 1004316-88-4
26
Didanosine Approved Phase 4 69655-05-6 50599
27
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
28
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
29
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
30
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
31
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
32
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
33
Colchicine Approved Phase 4 64-86-8 6167 2833
34
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
35
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
36
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
37
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
38
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
39
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
40
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
41
Lopinavir Approved Phase 4 192725-17-0 92727
42
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
43
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
44
Nevirapine Approved Phase 4 129618-40-2 4463
45
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
46
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
47
Methionine Approved, Nutraceutical Phase 4 63-68-3 6137
48
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
49
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
50 Atazanavir Sulfate Phase 4

Interventional clinical trials:

(show top 50) (show all 1351)
# Name Status NCT ID Phase Drugs
1 Hepatitis C in Renal Transplant Recipients - Safety and Efficacy of a Conversion of Immunosuppression to High-dose Cyclosporine A and Its Impact on Hepatitis C Virus-replication, Parameters of Liver Function and Glucose Tolerance. An Open Label Trial. Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
2 Efficacy and Safety of Daclatasvir Plus Asunaprevir Treatment in Patients With Chronic Hepatitis C : Prospective Cohort Study Unknown status NCT02639585 Phase 4 Daclinza and Sunvepra
3 Efficacy and Safety of a Hansenula-derived Pegylated Interferon α2a (Reiferon Retard®) in Treatment of Patients With Chronic Hepatitis C Virus Infection: A National Multi-center Phase IV Open Label Non-Randomized Trial Unknown status NCT01649245 Phase 4 Reiferon retard
4 A Randomized, Multi-center, Phase IV Open-label Study Evaluating the Antiviral Efficacy of Addition of Vitamin D in Patients With Treatment Naïve Chronic Hepatitis C Receiving Peginterferon Alfa-2a Plus Ribavirin Unknown status NCT01439776 Phase 4
5 Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C Unknown status NCT03022006 Phase 4 elbasvir, grazoprevir
6 Randomized, Multi-Center, Partially Placebo-Controlled Phase IV-Study to Compare Efficacy and Tolerability of 48-Week Combined Therapy With Peginterferon Alfa-2a, Ribavirin and Amantadine Sulphate Versus Placebo in Untreated Patients With Chronic Hepatitis C Virus-Genotype-1-Infection Unknown status NCT00127777 Phase 4 Amantadine sulphate (in addition to standard treatment)
7 Efficacy of Pentoxyfylline Addition to a Treatment Scheme Based on Interferon Alpha and Ribavirin on Hepatitis C Virus Coinfected HIV Patients, Considering Interleukin 28B Polymorphism rs12979860 Unknown status NCT02008214 Phase 4 Pentoxifylline;Placebo
8 Insulin Therapy in the Inpatient Management of Cirrhotic Patients With Type 2 Diabetes Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
9 An Efficacy and Safety Study Comparing Pegylated-Interferon and Ribavirin Plus Metformin to Pegylated-Interferon and Ribavirin in the Treatment of naïve Patients With Genotype 1 Chronic HCV Infection and Insulin Resistance Unknown status NCT00370617 Phase 4 metformin
10 Open, Multicentre,Randomized Phase IV Trial to Evaluate Efficacy/Safety to Extend Treatment Duration With Peginterferon Alfa-2a+High Dose of Ribavirin Supporting Epo β in Treatment of CHC in HIV-HCV Patients Who Not Clear Virus at Week 4 Unknown status NCT00526448 Phase 4 ribavirin;ribavirin;Peginterferon alfa-2a;epoetin beta
11 An Open-label, Multi-center, Randomized Study Comparing the Effects of Oral Hypoglycemic Agents on Viral Kinetics of Chronic Hepatitis C Patients Receiving Pegylated Interferon Alfa 2b Plus Ribavirin Unknown status NCT01025765 Phase 4 Pioglitazone;Acarbose;Metformin
12 A Pilot Study to Treat Patients With Chronic HCV Genotype 1 and ESRD Receiving Hemodialysis and Naïve to Prior HCV Therapy With Peginterferon Alfa-2b, the Maximally Tolerated Ribavirin Dose and Boceprevir Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
13 Phase IV Study of Effectiveness of Interferon and Ribavirin Treatment in Thalassemia Major Patients With Chronic Viral Hepatitis C Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
14 The Employing of the Bio-Hep-B PreS1/PreS2/S Hepatitis B Virus (HBV) Vaccine in New Born Babies From HBV Positive Palestinian Mothers Unknown status NCT01133184 Phase 4
15 Pilot Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2) Unknown status NCT02768545 Phase 4 Ezetimibe
16 A Single Center, Prospective Phase IV, Open-Label, Randomized Trial Comparing the Efficacy , Tolerability, and Safety of Quadritherapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide + Alfacalcidol ( Bon-One ®) ) Versus Triple Therapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide) Versus the Standard of Care Regimen(Reiferon Retard® + Ribavirin) in the Treatment of Naïve Chronic Hepatitis- C Among the Egyptian Population. Effectiveness Will be Evaluated Based on Sustained Viral Response (SVR) Unknown status NCT01896609 Phase 4 Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
17 An Open Label, Randomized, Parallel Design Estimation Pilot Study to Compare the Effectiveness of 36 vs 48 Wks PegIntron Plus Ribavirin Treatment for HCV Patients Without Rapid Virologic Response(RVR) But With Undetectable HCV RNA at wk 8 Unknown status NCT01683786 Phase 4 Pegintron + Riba
18 Personalized Medicine in HCV Chronic Infection. Endothelial Dysfunction and Subclinical Atheromatosis in Patients With HCV Infection. Characterization and Potential Reversibility With Direct Antiviral Agents. Unknown status NCT02802280 Phase 4
19 Direct Observed Therapy With Ledipasvir/Sofosbuvir in Treatment-naïve Patients With Chronic Genotype 1 HCV (Hepatitis C Virus) Infection Receiving Opiate Substitution Therapy Unknown status NCT02638233 Phase 4 Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)
20 An Open-label, Randomised Pilot Study Comparing the Efficacy, Safety and Tolerability of Raltegravir With Protease Inhibitor-based Therapy in Treatment-naïve, HIV/Hepatitis C Co-infected Injecting Drug Users Receiving Methadone Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
21 Generic Velpatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Completed NCT03250910 Phase 4 Sofosbuvir and Velpatasvir;Ribavirin
22 A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotypes 1-6 Infection and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤ 1 Completed NCT03212521 Phase 4 glecaprevir/pibrentasvir
23 Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection Completed NCT01097395 Phase 4 ribavirin
24 A Multicenter Study Evaluating the Efficacy and Safety of 12 Weeks Versus 24 Weeks Peginterferon Alfa-2a 40KD Combination Therapy With Ribavirin in Interferon Naïve Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Completed NCT00143000 Phase 4 Peginterferon alfa-2a 40KD and Ribavirin
25 A Prospective, Single-center, Open-label, Pilot Study to Investigate the Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients. Completed NCT01469884 Phase 4 Everolimus;Cyclosporine;Tacrolimus
26 A Multi-Site, Open-Label, Partially-Randomized Trial of the Efficacy and Safety of Fixed Dose Elbasvir/Grazoprevir (EBR/GZR) Based Regimens in French Subjects With Chronic Hepatitis C Virus (HCV) Genotype 4 Infection Completed NCT03111108 Phase 4 MK-5172A (EBR/GZR FDC [50 mg/100 mg])
27 A Phase 4, Multicenter, Open Label Study to Investigate the Efficacy and Safety of an All Oral Combination of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis VALOR-HCV: Veterans Affairs alL Oral Regimen of SOF+RBV in GT2 HCV Completed NCT02128542 Phase 4 Sofosbuvir;RBV
28 A Pilot Study to Evaluate Anti-Hepatitis C Virus Effect of Maraviroc in Patients Co-infected With Human Immunodeficiency Virus (HIV) and Hepatitis C Completed NCT02881762 Phase 4 Maraviroc
29 Study of the Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With and Without Post-hepatitis C Cirrhosis Completed NCT02992457 Phase 4 Sofosbuvir;Ribavirin;Pegylated-interferon alfa-2a;Simeprevir;Daclatasvir;Ritaprevir, paritaprevir, ombetasvir;Sofosbuvir and Ledipasvir;Salvage therapy
30 A Study of the Antiviral Activity of Metformin as an Anti-Hepatitis C Virus Agent in Patients With Chronic Hepatitis C Virus Infection Completed NCT02972723 Phase 4 Metformin
31 Pharmacokinetics of Buprenorphine and Naloxone in Subjects With Mild to Severe Hepatic Impairment (Child-Pugh Classes, A, B, and C), in HCV-Seropositive Subjects, and in Healthy Volunteers Completed NCT01846455 Phase 4 2.0mg Buprenorphine/0.5mg Naloxone;Promethazine
32 A Phase Iv Single-Arm Open-Label Non-Randomized Study To Evaluate The Safety And Pharmacokinetics Of Nelfinavir (Viracept, A430) 1250mg Twice Daily (250mg Or 625mg Forms) With Lamivudine/Zidovudine (Combivir) Background Therapy In Hiv/Hepatitis C Virus (Hcv) Co-Infected Subjects With Hepatic Dysfunction. Completed NCT00141284 Phase 4 nelfinavir 1,250 mg twice daily;Zidovudine 300 mg twice daily;Lamivudine 150 mg twice daily
33 Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World Completed NCT02964091 Phase 4 sofosbuvir/ledipasvir
34 Interferon Alfa Sensitivity in HIV/HCV Coinfected Persons Before and After Antiretroviral Therapy Completed NCT01285050 Phase 4 Antiretroviral therapy (ART);raltegravir;Emtricitabine and tenofovir disoproxil fumarate
35 Randomized Clinical Trial to Assess the Effectiveness of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 1 (TNT-1 Study) Completed NCT02624063 Phase 4 Daclatasvir + Sofosbuvir;Simeprevir + Sofosbuvir
36 Role of Rapid Virologic Response in Determining Treatment Duration of Peginterferon Alfa-2b/Ribavirin in Chronic Hepatitis C Genotype 4 Completed NCT00277862 Phase 4 Pegylated IFN- alpha 2b;Ribavirin
37 Tailored Treatment of Hepatitis C Genotype 1 Completed NCT00910975 Phase 4 Peg-interferon-alfa2a (Pegasys);Ribavirin (Copegus)
38 Low Dose Treatment of Ribavirin in Combination With PEG-IFN Alfa-2b in CHC Patients With genotype1 High Viral Load and Low Body Weight Completed NCT00686777 Phase 4 Ribavirin
39 Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study Completed NCT02220868 Phase 4 Sofosbuvir, Ribavirin, and Stribild
40 Post-marketing Clinical Trial of Pegasys® 180μg for Subcutaneous Injection in Patients With Chronic Hepatitis C. General Clinical Study in Interferon (IFN)-Treated and IFN-untreated Chronic Hepatitis C Patients, Except for Those Infected With High Viral Load of Genotype 1b Completed NCT00245414 Phase 4 Pegasys®;Pegasys®
41 The Clinical Utility of Monitoring for Human Herpesvirus-6 (HHV-6) and Human Herpesvirus-7 (HHV-7) After Liver Transplant: A Randomized Trial Completed NCT00242099 Phase 4
42 Influence of Marker of Insulin Resistance Upon HCV Treatment Responses to PEG Intron and Rebetol Therapy Completed NCT00351871 Phase 4 PEG-Intron Plus REBETOL
43 Randomized, Controlled, Open Label, Pilot Study to Evaluate Fosamprenavir Activity on Genotype 1 Hepatitis C Virus (HCV) Infection Evolution in Human Immunodeficiency Virus (HIV) Co-infected Subjects With Antiretroviral Treatment Including Fosamprenavir Completed NCT01222611 Phase 4 Fosamprenavir
44 Efficacy and Safety Study of Sofosbuvir Containing Regimens in Subjects With Chronic Hepatitis C Virus Genotype 2 Infection Completed NCT02482077 Phase 4 SOF+RBV;SOF+DCV;LDV/SOF
45 Treatment of Acute Hepatitis C Virus in HIV Co-Infection Completed NCT00845676 Phase 4 Pegylated interferon alfa-2a + Ribavirin
46 LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients Completed NCT02631772 Phase 4 Sofosbuvir/Ledipasvir x 12 weeks;Sofosbuvir/Ledipasvir + Ribavirin x 12 weeks
47 Treatment of Recently Acquired Hepatitis C Virus Infection Completed NCT01336010 Phase 4 Peginterferon alfa-2a;Ribavirin
48 Treatment of Acute Hepatitis C Virus Infection in Injection Drug Users With Pegylated Interferon for 24 Weeks Completed NCT00194480 Phase 4 Pegylated Interferon
49 TEN Switch - An Observational Phase IV Study to Evaluate the Safety and Efficacy of Substituting Tenofovir for Didanosine in Virologically Controlled HIV-infected Patients Co-infected With Hepatitis C Virus. Completed NCT00358696 Phase 4 tenofovir
50 An Open-Label, Randomized, Prospective Multicenter Study To Compare The Efficacy And Safety Among 3 Immunosuppressant Treatment Regimens In Patients Receiving A Liver Transplant For ESLD Caused By Chronic Hepatitis C Completed NCT00163657 Phase 4 Daclizumub;Tacrolimus;Cyclosporine;MMF

Search NIH Clinical Center for Hepatitis C Virus

Genetic Tests for Hepatitis C Virus

Genetic tests related to Hepatitis C Virus:

# Genetic test Affiliating Genes
1 Hepatitis C Virus, Susceptibility to 29 CCR5 IFNG IFNL3 PTPRC
2 Hepatitis C Virus Infection, Response to Therapy of 29

Anatomical Context for Hepatitis C Virus

MalaCards organs/tissues related to Hepatitis C Virus:

41
Liver, Testes, T Cells, Kidney, B Cells, Bone, Thyroid

Publications for Hepatitis C Virus

Articles related to Hepatitis C Virus:

(show top 50) (show all 30043)
# Title Authors PMID Year
1
A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. 38 8 71
17215375 2007
2
Altered CD45 expression in C77G carriers influences immune function and outcome of hepatitis C infection. 8 71
16505159 2006
3
The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. 8 71
15863470 2005
4
Interferon-inducible protein SCOTIN interferes with HCV replication through the autolysosomal degradation of NS5A. 38 8
26868272 2016
5
MCPIP1 suppresses hepatitis C virus replication and negatively regulates virus-induced proinflammatory cytokine responses. 38 8
25225661 2014
6
IPS-1 is essential for type III IFN production by hepatocytes and dendritic cells in response to hepatitis C virus infection. 38 8
24532585 2014
7
A class II phosphoinositide 3-kinase plays an indispensable role in hepatitis C virus replication. 38 8
24055031 2013
8
IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. 38 8
23712427 2013
9
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. 38 8
23291588 2013
10
Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. 38 8
22231557 2012
11
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. 38 8
21516087 2011
12
Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1. 38 8
20935628 2010
13
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. 38 8
20173735 2010
14
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. 38 8
19965718 2010
15
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. 38 8
19759533 2009
16
A genome-wide genetic screen for host factors required for hepatitis C virus propagation. 38 8
19717417 2009
17
Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus. 38 8
17804490 2007
18
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. 38 8
17325668 2007
19
Apolipoprotein epsilon3 allele is associated with persistent hepatitis C virus infection. 38 8
16299033 2006
20
Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. 38 8
16141076 2005
21
Unscrambling hepatitis C virus-host interactions. 38 8
16107831 2005
22
Unravelling hepatitis C virus replication from genome to function. 38 8
16107832 2005
23
Evasion of intracellular host defence by hepatitis C virus. 38 8
16107833 2005
24
Adaptive immune responses in acute and chronic hepatitis C virus infection. 38 8
16107834 2005
25
Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. 38 8
15893726 2005
26
HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. 38 8
15297676 2004
27
Pathophysiology of hepatitis C virus infection and related liver disease. 38 8
15036326 2004
28
Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. 38 8
12702807 2003
29
L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. 38 8
12676990 2003
30
Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. 38 8
12634366 2003
31
The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. 38 8
12356718 2002
32
Subversion of cell signaling pathways by hepatitis C virus nonstructural 5A protein via interaction with Grb2 and P85 phosphatidylinositol 3-kinase. 38 8
12186904 2002
33
Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. 38 8
11781363 2002
34
Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. 38 8
11781364 2002
35
Identification of eIF2Bgamma and eIF2gamma as cofactors of hepatitis C virus internal ribosome entry site-mediated translation using a functional genomics approach. 38 8
10900014 2000
36
Hepatitis C virus core protein-induced loss of LZIP function correlates with cellular transformation. 38 8
10675342 2000
37
Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. 38 8
10609818 1999
38
Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. 38 8
10535997 1999
39
Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. 38 8
10390359 1999
40
NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. 38 8
10318918 1999
41
Binding of hepatitis C virus to CD81. 38 8
9794763 1998
42
RACK1 controls IRES-mediated translation of viruses. 8
25416947 2014
43
IFN-λ receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-λ3 genotype and with nonresponsiveness to IFN-α therapies. 8
24752298 2014
44
A disease-associated polymorphism alters splicing of the human CD45 phosphatase gene by disrupting combinatorial repression by heterogeneous nuclear ribonucleoproteins (hnRNPs). 71
21507955 2011
45
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. 8
20547162 2010
46
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. 8
19749757 2009
47
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. 8
19749758 2009
48
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. 8
19684573 2009
49
An investigation of the C77G and C772T variations within the human protein tyrosine phosphatase receptor type C gene for association with multiple sclerosis in an Australian population. 71
19111528 2009
50
Interaction between RANTES promoter variant and CCR5Delta32 favors recovery from hepatitis B. 71
19017985 2008

Variations for Hepatitis C Virus

ClinVar genetic disease variations for Hepatitis C Virus:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 CCR5 NM_000579.3(CCR5): c.554_585del (p.Ser185fs) deletion protective,risk factor rs333 3:46414947-46414978 3:46373456-46373487
2 PTPRC PTPRC, 77C-G single nucleotide variant risk factor
3 IFNG NM_000619.2(IFNG): c.-893C> G single nucleotide variant drug response rs2069707 12:68554288-68554288 12:68160508-68160508
4 KRT18 NM_000224.3(KRT18): c.1230C> G (p.Thr410=) single nucleotide variant not provided rs386834225 12:53346563-53346563 12:52952779-52952779
5 KRT18 NM_000224.3(KRT18): c.282C> T (p.Tyr94=) single nucleotide variant not provided rs386834224 12:53343239-53343239 12:52949455-52949455
6 KRT18 NM_000224.3(KRT18): c.134G> C (p.Arg45Pro) single nucleotide variant not provided rs200221269 12:53343091-53343091 12:52949307-52949307
7 KRT8 NM_002273.4(KRT8): c.1033G> T (p.Ala345Ser) single nucleotide variant not provided rs386834221 12:53292632-53292632 12:52898848-52898848
8 KRT8 NM_002273.4(KRT8): c.1340C> T (p.Ala447Val) single nucleotide variant not provided rs386834223 12:53291324-53291324 12:52897540-52897540
9 KRT8 NM_002273.4(KRT8): c.1412G> A (p.Gly471Glu) single nucleotide variant not provided rs386834222 12:53291252-53291252 12:52897468-52897468

Cosmic variations for Hepatitis C Virus:

9 (show top 50) (show all 3365)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM1626018 ZXDB liver,NS,carcinoma,hepatocellular carcinoma c.1308C>A p.D436E 23:57593356-57593356 3
2 COSM1615665 ZSWIM1 liver,NS,carcinoma,hepatocellular carcinoma c.1399A>C p.S467R 20:45883991-45883991 3
3 COSM1602238 ZSCAN20 liver,NS,carcinoma,hepatocellular carcinoma c.2314G>T p.G772W 1:33494658-33494658 3
4 COSM6951673 ZRSR2 liver,NS,carcinoma,hepatocellular carcinoma c.304G>T p.E102* 23:15803788-15803788 3
5 COSM1616325 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.859A>G p.M287V 22:29049340-29049340 3
6 COSM3707827 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860L 20:49257501-49257501 3
7 COSM3707828 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860L 20:49257501-49257501 3
8 COSM1623051 ZNF853 liver,NS,carcinoma,hepatocellular carcinoma c.1610G>T p.G537V 7:6622601-6622601 3
9 COSM1612127 ZNF829 liver,NS,carcinoma,hepatocellular carcinoma c.829T>A p.F277I 19:36891962-36891962 3
10 COSM1618451 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.1741C>T p.L581L 4:145885684-145885684 3
11 COSM1611545 ZNF653 liver,NS,carcinoma,hepatocellular carcinoma c.1553A>C p.H518P 19:11485673-11485673 3
12 COSM1612685 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47V 19:52002156-52002156 3
13 COSM1612018 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.3900G>T p.K1300N 19:30557161-30557161 3
14 COSM1618219 ZNF518B liver,NS,carcinoma,hepatocellular carcinoma c.1624G>T p.E542* 4:10444705-10444705 3
15 COSM1624399 ZNF462 liver,NS,carcinoma,hepatocellular carcinoma c.6715G>T p.V2239L 9:106974156-106974156 3
16 COSM1609798 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1219C>G p.L407V 16:89734008-89734008 3
17 COSM1605856 ZNF26 liver,NS,carcinoma,hepatocellular carcinoma c.1010C>T p.T337I 12:133010889-133010889 3
18 COSM1602404 ZMYND12 liver,NS,carcinoma,hepatocellular carcinoma c.425-1G>T p.? 1:42440026-42440026 3
19 COSM1607880 ZFYVE26 liver,NS,carcinoma,hepatocellular carcinoma c.663C>A p.A221A 14:67807621-67807621 3
20 COSM3661787 ZFR liver,NS,carcinoma,hepatocellular carcinoma c.2882C>T p.P961L 5:32364229-32364229 3
21 COSM1270878 ZFP36L2 liver,NS,carcinoma,hepatocellular carcinoma c.910T>G p.S304A 2:43224894-43224894 3
22 COSM1612900 ZFP28 liver,NS,carcinoma,hepatocellular carcinoma c.1865G>A p.C622Y 19:56554650-56554650 3
23 COSM3663890 ZFHX4 liver,NS,carcinoma,hepatocellular carcinoma c.10601C>G p.S3534C 8:76864315-76864315 3
24 COSM6969923 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.10852C>A p.P3618T 16:72787424-72787424 3
25 COSM3717069 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.8342A>G p.Q2781R 16:72794340-72794340 3
26 COSM6219678 ZFHX3 liver,NS,carcinoma,hepatocellular carcinoma c.9997C>T p.Q3333* 16:72788279-72788279 3
27 COSM1613453 ZEB2 liver,NS,carcinoma,hepatocellular carcinoma c.1141A>G p.M381V 2:144400046-144400046 3
28 COSM3717124 ZCCHC14 liver,NS,carcinoma,hepatocellular carcinoma c.71A>T p.Q24L 16:87491757-87491757 3
29 COSM1608898 ZC3H7A liver,NS,carcinoma,hepatocellular carcinoma c.2866A>G p.N956D 16:11751367-11751367 3
30 COSM3705381 ZBTB41 liver,NS,carcinoma,hepatocellular carcinoma c.1700G>A p.R567K 1:197178489-197178489 3
31 COSM1601838 ZBTB40 liver,NS,carcinoma,hepatocellular carcinoma c.3339C>A p.F1113L 1:22524258-22524258 3
32 COSM1610770 ZBTB4 liver,NS,carcinoma,hepatocellular carcinoma c.454G>T p.G152C 17:7466348-7466348 3
33 COSM1601260 ZBTB37 liver,NS,carcinoma,hepatocellular carcinoma c.620G>C p.S207T 1:173870845-173870845 3
34 COSM1624206 ZBTB10 liver,NS,carcinoma,hepatocellular carcinoma c.2136A>G p.T712T 8:80518852-80518852 3
35 COSM1624207 ZBTB10 liver,NS,carcinoma,hepatocellular carcinoma c.2311A>G p.I771V 8:80519295-80519295 3
36 COSM1616586 ZBED4 liver,NS,carcinoma,hepatocellular carcinoma c.2225A>C p.E742A 22:49885887-49885887 3
37 COSM1624117 YTHDF3 liver,NS,carcinoma,hepatocellular carcinoma c.1568A>G p.N523S 8:63187582-63187582 3
38 COSM1603361 YME1L1 liver,NS,carcinoma,hepatocellular carcinoma c.2006A>G p.H669R 10:27116230-27116230 3
39 COSM1617254 YEATS2 liver,NS,carcinoma,hepatocellular carcinoma c.501C>T p.N167N 3:183722100-183722100 3
40 COSM3663693 XPO7 liver,NS,carcinoma,hepatocellular carcinoma c.806A>G p.Y269C 8:21977812-21977812 3
41 COSM1609152 XPO6 liver,NS,carcinoma,hepatocellular carcinoma c.882C>T p.G294G 16:28156289-28156289 3
42 COSM6957749 XPO1 liver,NS,carcinoma,hepatocellular carcinoma c.301+1G>C p.? 2:61522610-61522610 3
43 COSM1624082 XKR4 liver,NS,carcinoma,hepatocellular carcinoma c.1076A>G p.D359G 8:55523350-55523350 3
44 COSM1613650 XIRP2 liver,NS,carcinoma,hepatocellular carcinoma c.9350G>C p.R3117P 2:167250742-167250742 3
45 COSM3660541 XIRP1 liver,NS,carcinoma,hepatocellular carcinoma c.142C>A p.Q48K 3:39189304-39189304 3
46 COSM1625463 XIAP liver,NS,carcinoma,hepatocellular carcinoma c.493G>T p.A165S 23:123886155-123886155 3
47 COSM3663909 WWP1 liver,NS,carcinoma,hepatocellular carcinoma c.210-2A>G p.? 8:86381503-86381503 3
48 COSM1625309 WWC3 liver,NS,carcinoma,hepatocellular carcinoma c.1121C>A p.S374Y 23:10117180-10117180 3
49 COSM1621161 WTAP liver,NS,carcinoma,hepatocellular carcinoma c.283C>T p.Q95* 6:159748200-159748200 3
50 COSM6909096 WT1 liver,NS,carcinoma,hepatocellular carcinoma c.1019T>G p.L340* 11:32396283-32396283 3

Expression for Hepatitis C Virus

LifeMap Discovery
Genes differentially expressed in tissues of Hepatitis C Virus patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CXCL10 chemokine (C-X-C motif) ligand 10 Liver + 4.26 0.000
2 CXCL11 chemokine (C-X-C motif) ligand 11 Liver + 3.57 0.000
3 LOC553137 uncharacterized LOC553137 Liver - 3.21 0.000
4 CXCL9 chemokine (C-X-C motif) ligand 9 Liver + 3.07 0.000
Search GEO for disease gene expression data for Hepatitis C Virus.

Pathways for Hepatitis C Virus

Pathways related to Hepatitis C Virus according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.62 PTPRC IFNL3 IFNG CCR5
2
Show member pathways
11.59 CLDN9 CLDN6 CLDN1
3 11.28 PTPRC IFNG CCR5
4 11.09 PTPRC CLDN9 CLDN6 CLDN1

GO Terms for Hepatitis C Virus

Cellular components related to Hepatitis C Virus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.86 SCARB1 PTPRC PSMA7 KRT8 KRT18 GPT
2 bicellular tight junction GO:0005923 9.33 CLDN9 CLDN6 CLDN1
3 apicolateral plasma membrane GO:0016327 8.96 KRT8 CLDN6
4 cell periphery GO:0071944 8.8 PTPRC KRT8 KRT18

Biological processes related to Hepatitis C Virus according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.67 PTPRC IFNG CCR5
2 defense response to virus GO:0051607 9.67 PTPRC IFNL4 IFNL3 IFNG
3 extrinsic apoptotic signaling pathway GO:0097191 9.5 KRT8 KRT18 IFNG
4 negative thymic T cell selection GO:0045060 9.48 PTPRC ATG5
5 hepatocyte apoptotic process GO:0097284 9.46 KRT8 KRT18
6 positive regulation of immune response GO:0050778 9.43 IFNL4 IFNL3
7 cell-cell junction organization GO:0045216 9.43 CLDN9 CLDN6 CLDN1
8 viral entry into host cell GO:0046718 9.43 SCARB1 CLEC4M CLDN9 CLDN6 CLDN1 CD81
9 regulation of phagocytosis GO:0050764 9.4 SCARB1 PTPRC
10 viral process GO:0016032 9.4 TBC1D20 SCARB1 PSMA7 KRT8 KRT18 CLEC4M
11 calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules GO:0016338 9.33 CLDN9 CLDN6 CLDN1

Molecular functions related to Hepatitis C Virus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural molecule activity GO:0005198 9.26 KRT18 CLDN9 CLDN6 CLDN1
2 virus receptor activity GO:0001618 9.17 SCARB1 CLEC4M CLDN9 CLDN6 CLDN1 CD81
3 protein binding GO:0005515 10.06 TBC1D20 SCARB1 PTPRC PSMA7 PNKD KRT8

Sources for Hepatitis C Virus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....